Should thaldex (thalidomide-dexamethasone) replace VAD (vincristine-adriamycin-dexamethasone) as induction treatment for newly diagnosed multiple myeloma? The Indian perspective

被引：0
|
作者：
Pandey, Ritwik [1 ]
Patel, Kirti M. [1 ]
Shah, Sandip A. [1 ]
Patel, Apurva A. [1 ]
机构：
[1] Gujarat Canc Res Inst, Ahmadabad, Gujarat, India
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [31] Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
    HM Lokhorst
    P Sonneveld
    JJ Cornelissen
    P Joosten
    M van Marwijk Kooy
    J Meinema
    HK Nieuwenhuis
    MHJ van Oers
    DJ Richel
    CN Segeren
    G Veth
    LF Verdonck
    PW Wijermans
    Bone Marrow Transplantation, 1999, 23 : 317 - 322
  • [32] Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
    Lokhorst, HM
    Sonneveld, P
    Cornelissen, JJ
    Joosten, P
    Kooy, MV
    Meinema, J
    Nieuwenhuis, HK
    van Oers, MHJ
    Richel, DJ
    Segeren, CN
    Veth, G
    Verdonck, LF
    Wijermans, PW
    BONE MARROW TRANSPLANTATION, 1999, 23 (04) : 317 - 322
  • [33] Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
    Cavo, Michele
    Pantani, Lucia
    Petrucci, Maria Teresa
    Patriarca, Francesca
    Zamagni, Elena
    Donnarumma, Daniela
    Crippa, Claudia
    Boccadoro, Mario
    Perrone, Giulia
    Falcone, Antonietta
    Nozzoli, Chiara
    Zambello, Renato
    Masini, Luciano
    Furlan, Anna
    Brioli, Annamaria
    Derudas, Daniele
    Ballanti, Stelvio
    Dessanti, Maria Laura
    De Stefano, Valerio
    Carella, Angelo Michele
    Marcatti, Magda
    Nozza, Andrea
    Ferrara, Felicetto
    Callea, Vincenzo
    Califano, Catello
    Pezzi, Annalisa
    Baraldi, Anna
    Grasso, Mariella
    Musto, Pellegrino
    Palumbo, Antonio
    BLOOD, 2012, 120 (01) : 9 - 19
  • [34] Thalidomide and dexamethasone for newly diagnosed multiple myeloma: Is this really the standard of care?
    Nabhan, Chadi
    Bitran, Jacob D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2967 - 2968
  • [35] TREATMENT OF REFRACTORY MULTIPLE-MYELOMA WITH VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE, AND WITH REPEATED APPLICATION OF CYCLOPHOSPHAMIDE (C-VAD)
    ADAM, Z
    ELBL, L
    VORLICEK, J
    HAJEK, R
    HAJEK, D
    HEJLOVA, N
    KRALOVA, E
    NOVOTNA, H
    ACTA MEDICA AUSTRIACA, 1994, 21 (04) : 111 - 115
  • [36] TREATMENT OF EVOLVED MULTIPLE-MYELOMA USING STRONG DOSES OF ADRIAMYCIN, VINCRISTINE AND CONTINUOUS PERFUSION OF DEXAMETHASONE (VAD)
    MONCONDUIT, M
    GROSBOIS, B
    LELOET, X
    BERNARD, JF
    MICHAUX, JL
    JOUET, JP
    LAPORTE, JP
    TILLY, H
    NAJMAN, A
    PIGUET, H
    DESHAYES, P
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1985, 27 (02): : 90 - 90
  • [37] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
    Hye Jin Kim
    Sung-Soo Yoon
    Dong Soon Lee
    Sang Kyun Sohn
    Hyeon Seok Eom
    Jung Lim Lee
    Joo Seup Chung
    Kihyun Kim
    Cheolwon Suh
    Jong Ho Won
    Jin Seok Kim
    Joon Seong Park
    Hye Jin Kang
    Chu Myong Seong
    Cheol Soo Kim
    Sang Jae Lee
    Jae Hoon Lee
    Annals of Hematology, 2012, 91 : 249 - 256
  • [38] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
    Kim, Hye Jin
    Yoon, Sung-Soo
    Lee, Dong Soon
    Sohn, Sang Kyun
    Eom, Hyeon Seok
    Lee, Jung Lim
    Chung, Joo Seup
    Kim, Kihyun
    Suh, Cheolwon
    Won, Jong Ho
    Kim, Jin Seok
    Park, Joon Seong
    Kang, Hye Jin
    Seong, Chu Myong
    Kim, Cheol Soo
    Lee, Sang Jae
    Lee, Jae Hoon
    ANNALS OF HEMATOLOGY, 2012, 91 (02) : 249 - 256
  • [39] Thalidomide/Dexamethasone Induction Therapy in Newly Diagnosed Myeloma Patients with Renal Failure
    Tosi, P.
    Tacchetti, P.
    Zamagni, E.
    Tacchetti, P.
    Ceccolini, M.
    Perrone, G.
    Brioli, A.
    Pallotti, M. C.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S30 - S30
  • [40] Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study
    Cavo, Michele
    Perrone, Giulia
    Buttignol, Silvia
    Calabrese, Elisabetta
    Galli, Monica
    Bringhen, Sara
    Spadano, Tonino
    Baldini, Luca
    Caravita, Tommaso
    Nozzoli, Chiara
    Brioli, Annamaria
    Masini, Luciano
    Furlan, Anna
    Pantani, Lucia
    Derudas, Daniele
    Ballanti, Stelvio
    Pisani, Francesco
    De Stefano, Valerio
    Catania, Gioacchino
    Castagna, Luca
    Ferrara, Felicetto
    Callea, Vincenzo
    Musto, Pellegrino
    Zamagni, Elena
    Baccarani, Michele
    BLOOD, 2010, 116 (21) : 25 - 25
12345